StemCell Therapy

[190+ Pages PDF Report] Facts & Factors (FnF) published a market research report onGene Therapy Market: By Size, Share, Growth Factors, Top Players, COVID-19 Analysis and Forecast, 2020-2026that includes a research report with TOC including a list of tables and figures in its research offerings.

Gene Therapy Market Report: Industry Insights, 2020-2026

This multi-client research study on theGene Therapy marketprovides in-depth research and analysis into Gene Therapy industry trends, market developments and technological insights. The report provides data and analysis of Gene Therapy penetration across application segments across countries and regions. The report presents a strategic analysis of the Gene Therapyy market through key drivers, challenges, opportunities, and growth contributors.

The global Gene Therapy market delivers value to customers through reliable market size for 2020 on the basis of demand and price analysis. The report presents near term and long term forecast of the addressable Gene Therapy market size to 2026.

The report presents an introduction to the Gene Therapy market in 2020, analyzing the COVID-19 impact both quantitatively and qualitatively.

Request an Exclusive FREE SAMPLE REPORT of Gene Therapy Market:https://www.fnfresearch.com/sample/gene-therapy-market-by-type-germ-line-gene

(The sample of this report is readily available on request).

The FREE PDF Sample Report Includes:

(Note: The sample of this report is updated with COVID-19 impact analysis before delivery)

Some of Following Top Market Players Profile Included in This Report:

2020 Gene Therapy Market: COVID-19 Impact Analysis

The global rise of COVID-19 has many businesses struggling and confused about what steps to take to minimize the economic impact. A simple look at the stock market will tell you that coronavirus has led to a volatile economy, but there are numerous other factors at play.

The long term COVID-19 impact on the business industry is largely still unknown; hence,Facts and Factors market researchanalysts have already covered the effects of COVID-19 on the business industry at a large level, as well as global and regional levels. Through our coverage below, get a better understanding of the business and economic implications coronavirus has on trends like remote working, consumer shopping behavior, global advertising spend, and essential industries like food, medical, travel, and transportation.

Download the Free Sample Report PDF Brochure Including COVID-19 Business Impact:https://www.fnfresearch.com/sample/gene-therapy-market-by-type-germ-line-gene

Gene Therapy Market 2020: Research Scope & Coverage

The report covers Gene Therapy market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography. The market size analysis gives the market size covering both the historic growth of the market, the impact of the COVID 19 virus, and forecasting its recovery. The report also provides a comprehensive analysis of current & future trends and emerging avenues for the growth of this market along with this research also offers an insight into the competitive landscape in terms of new technological developments, untapped segments, and value chain analysis.

The report, Gene Therapy Market, provides up-to-date information about market size, share shifts, and potential risks, as well as in-depth knowledge of products and services, which can help in planning and in executing category management activities. It focuses on the cost-saving aspects of procurement and on providing insights that can lead to the optimization of category spend.

Get Free Customized Copy of Gene Therapy Market Report @https://www.fnfresearch.com/customization/gene-therapy-market-by-type-germ-line-gene

(We customize your report according to your research need. Ask our sales team for report customization.)

Competitive Landscape

The market appears to be fragmented and with the presence of several. This Gene Therapy market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the markets competitive landscape and offering information on the products offered by companies.

Key Takeaways from this Gene Therapy Market Report

About Us:

Facts & Factorsis a leading market research company and offers customized research reports and consulting services. Facts & Factors aims at management consulting, industry chain research, and advanced research to assist our clients by providing planned revenue model for their business. Our report and services are used by prestigious academic institutions, start-ups, and companies globally to understand the international and regional business background.

Contact Us (Corporate Office):Facts & FactorsA 2108, Sargam,Nanded City,Sinhagad Road,Pune 411041, IndiaUSA: +1-347-989-3985Email:[emailprotected]Web:https://www.fnfresearch.com

Read more:
Know Top Players and Growing Trends in Gene Therapy Market 2020 Research Report and Industry Forecast till 2026 - Galus Australis

MarketsandResearch.biz has published the latest market research study on Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market 2020 by Company, Type and Application, Forecast to 2025 which investigates a few critical features of the market such as industry condition, division examination, market insights. The report studies the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market share, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels. The report has referenced down to earth ideas of the market in a straightforward and unassuming way in this report. The research contains the categorization of the market by top players/brands, region, type, and end-user. The report exhaustive essential investigation of current market trends, opportunities, challenges, and detailed competitive analysis of the industry players in the market.

The research report has comprehensively included numbers and figures with the help of graphical and pictorial representation which embodies more clarity on the global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market. Then the report delivers key information about market players such as company overview, total revenue (financials), market potential, global presence, as well as market share, prices, production sites and facilities, products offered, and strategies adopted by them. Market status and outlook of global and major regions, from angles of players, countries, product types, and end industries have been analyzed.

NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/83910

Key strategic manufacturers included in this report: BioReliance, Richter-Helm, UniQure, Cobra Biologics, MassBiologics, Oxford BioMedica, Lonza, MolMed, FinVector, FUJIFILM Diosynth Biotechnologies, Brammer Bio, bluebird bio, Aldevron, Spark Therapeutics, VGXI, Biovian, Eurogentec, Novasep, PlasmidFactory, Cell and Gene Therapy Catapult, Vigene Biosciences

Market Potential:

Key market vendors have been predicted to obtain the latest opportunities as there has been an increased emphasis on spending more on the work of research and development by many of the manufacturing companies. Also, many of the market contenders are forecasted to make a foray into the emerging economies to find new opportunities. The global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing market has gone through rapid business transformation by good customer relationships, drastic and competitive growth, significant changes within the market, and technological advancement in this market.

Geographically, this report is segmented into several key countries, with market size, growth rate, import and export of in these countries from 2015 to 2020, which covering: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), MENA (Saudi Arabia, UAE, Turkey and South Africa)

The market can be segmented into product types as: AAV, Adenoviral, Lentiviral, Retroviral, Plasmid DNA, Other Vectors

The market can be segmented into applications as: Cancers, Inherited Disorders, Viral Infections, Others

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/83910/global-viral-vectors-non-viral-vectors-and-gene-therapy-manufacturing-market-2020-by-company-type-and-application-forecast-to-2025

Reasons for Buying Market Report:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

You May Check Also Other Reports

Global 3D Chips (3D IC) Market 2020 Industry Size, Share, Growth, Outlook, Segmentation, Comprehensive Analysis by 2025

Global Gig Economy Platforms Market 2020 Key Players, Comprehensive Research, SWOT Analysis and Forecast by 2025

Global GPS Watches for Kids Market 2020 by Key Players, Segmentation, Industry Growth, Opportunities and Forecast by 2025

Global Acrylic Protective Coating Market 2020 Report Presents Complete Summary, Marketplace Shares and Growth Opportunities by 2025

Global Dextrin for Food Market 2020 Key Players Data, Revenue, Future Development, Trend and Competitive Landscape Analysis by 2025

Here is the original post:
Global Viral Vectors, Non-Viral Vectors and Gene Therapy Manufacturing Market 2020 | Scope of Current and Future Industry 2026 - Good Night, Good...

Chicago, United States:The global Cell and Gene Therapy Market report offers a complete research study that includes accurate estimations of market growth rate and size for the forecast period 2020-2025. It offers a broad analysis of market competition, regional expansion, and market segmentation by type, application, and geography supported by exact market figures. The all-inclusive market research report also offers Porters Five Forces Analysis and profiles some of the leading players of the global Cell and Gene Therapy Market. It sheds light on changing market dynamics and discusses about different growth drivers, market challenges and restraints, and trends and opportunities in detail. Interested parties are provided with market recommendations and business advice to ensure success in the global Cell and Gene Therapy Market.

Top Key players cited in the report:Amgen Inc., bluebird bio, Inc., Dendreon Pharmaceuticals LLC., Fibrocell Science, Inc., Human Stem Cells Institute, Kite Pharma, Inc., Kolon TissueGene, Inc., Novartis AG, Orchard Therapeutics plc., Organogenesis Holdings Inc., Pfizer, Inc., RENOVA THERAPEUTICS, .

Get Free PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart): https://www.reporthive.com/request_sample/2369809

The final report will add the analysis of the Impact of Covid-19 in this report Cell and Gene Therapy Market

Cell and Gene Therapy Marketreports offers important insights which help the industry experts, product managers, CEOs, and business executives to draft their policies on various parameters including expansion, acquisition, and new product launch as well as analyzing and understanding the market trends.

Each segment of the global Cell and Gene Therapy market is extensively evaluated in the research study. The segmental analysis offered in the report pinpoints key opportunities available in the global Cell and Gene Therapy market through leading segments. The regional study of the global Cell and Gene Therapy market included in the report helps readers to gain a sound understanding of the development of different geographical markets in recent years and also going forth. We have provided a detailed study on the critical dynamics of the global Cell and Gene Therapy market, which include the market influence and market effect factors, drivers, challenges, restraints, trends, and prospects. The research study also includes other types of analysis such as qualitative and quantitative.

Global Cell and Gene Therapy Market: Competitive Rivalry

The chapter on company profiles studies the various companies operating in the global Cell and Gene Therapy market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Cell and Gene Therapy market participants in the past few years to remain ahead of the competition.

Global Cell and Gene Therapy Market: Regional Segments

The chapter on regional segmentation details the regional aspects of the global Cell and Gene Therapy market. This chapter explains the regulatory framework that is likely to impact the overall market. It highlights the political scenario in the market and the anticipates its influence on the global Cell and Gene Therapy market.

Request For Customization:https://www.reporthive.com/request_customization/2369809

Report Highlights

Table of Contents

Report Overview:It includes six chapters, viz. research scope, major manufacturers covered, market segments by type, Cell and Gene Therapy market segments by application, study objectives, and years considered.

Global Growth Trends:There are three chapters included in this section, i.e. industry trends, the growth rate of key producers, and production analysis.

Cell and Gene Therapy Market Share by Manufacturer:Here, production, revenue, and price analysis by the manufacturer are included along with other chapters such as expansion plans and merger and acquisition, products offered by key manufacturers, and areas served and headquarters distribution.

Market Size by Type:It includes analysis of price, production value market share, and production market share by type.

Market Size by Application:This section includes Cell and Gene Therapy market consumption analysis by application.

Profiles of Manufacturers:Here, leading players of the global Cell and Gene Therapy market are studied based on sales area, key products, gross margin, revenue, price, and production.

Cell and Gene Therapy Market Value Chain and Sales Channel Analysis:It includes customer, distributor, Cell and Gene Therapy market value chain, and sales channel analysis.

Market Forecast Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

Get Free Sample Copy of this report:https://www.reporthive.com/request_sample/2369809

About Us:Report Hive Research delivers strategic market research reports, statistical survey, and Industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of United States Business Leaders, Government Organizations, SMEs, Individual and Start-ups, Management Consulting Firms, and Universities etc. Our library of 600,000+ market reports covers industries like Chemical, Healthcare, IT, Telecom, Semiconductor, etc. in the USA, Europe Middle East, Africa, Asia Pacific. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio and application analysis etc.

The rest is here:
COVID-19 Impact on Cell and Gene Therapy Market Research, Size, Growth And Trends 2020 to 2025: Keyplayer-Amgen Inc., bluebird bio, Inc. - Scientect

Notice: This Content doesnt contain all the Information of the Report please fill the form (via link) and get all interesting information just one click in PDF with the latest update with chart and Table of Content

The report offers a systematic presentation of the existing trends, growth opportunities, market dynamics that are expected to shape the growth of the Cell Therapy Manufacturing Market. The various research methods and tools were involved in the market analysis, to uncover crucial information about the market such as current & future trends, opportunities, business strategies and more, which in turn will aid the business decision-makers to make the right decision in future.

This Report Covers Leading Companies Associated in Worldwide Cell Therapy Manufacturing Market: Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

We Do Offer Sample of this report. Kindly go through the following information in order to access the report.

Note- This report sample includes:

Brief Introduction to the research report. Table of Contents (Scope covered as a part of the study) Top players in the market Research framework (Structure Of The Report) Research methodology adopted by Coherent Market Insights

Get Sample Copy Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/1728

The report begins with a brief introduction and market overview of the Cell Therapy Manufacturing industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed along with current trends and policies in the industry.

The key players profiled in this report include:Pharmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

The PDF Research only provides a Table of Contents (ToC), the scope of the report and research framework of the report.

Get Free PDF Brochure Of this Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1728

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Cell Therapy Manufacturing

o The micro-level analysis is conducted based on its product types, end-user applications, and geographies

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Cell Therapy Manufacturing market

The research study can answer the following Key questions:

What will be the progress rate of the Cell Therapy Manufacturing Market for the conjecture period, 2020 2027?What are the prominent factors driving the Cell Therapy Manufacturing Market across different regions?Who are the major vendors dominating the Cell Therapy Manufacturing industry and what are their winning strategies?What will be the market scope for the estimated period?What are the major trends shaping the expansion of the industry in the coming years?What are the challenges faced by the Cell Therapy Manufacturing Market?

Table of Contents

Report Overview: It includes the Cell Therapy Manufacturing market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Cell Therapy Manufacturing market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Cell Therapy Manufacturing market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Cell Therapy Manufacturing market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report : https://www.coherentmarketinsights.com/insight/request-discount/1728

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific.

**BE SAFE AND STAY HOME**

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email: [emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

See original here:
Cell Therapy Manufacturing Market Growth, Demand, And Value Is Increasing In The Upcoming Years - The Daily Chronicle

AVROBIO, a US-based company, developing lentiviral-based gene therapies, has announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Companys investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease.

Get a complete list of the presentations,here.

What is AVR-RD-02: AVR-RD-02 consists of the patients own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. It is an ex vivo lentiviral-based investigational gene therapy. The stem cells are genetically modified to express functional glucocerebrosidase (GCase), which reduces levels of glucosylceramide and glucosylsphingosine, the accumulated substances which cause the symptoms of Gaucher disease.

How advanced is AVR-RD-02 development program: The Company is actively recruiting in Canada for its Phase 1/2 clinical trial of AVR-RD-02, which seeks to evaluate the safety and efficacy of the therapy in patients with Type 1 Gaucher disease.

What is an orphan drug designation: Orphan-drug designation provides special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. For a drug to qualify for orphan designation both the drug and the disease or condition must meet certain criteria specified in the ODA and FDAs implementing regulations at 21 CFR Part 316. Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing. A marketing application for a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.

What is the gene therapy pipeline like for the treatment of Gaucher disease: There are only a few gene therapy candidates that are being developed for Gaucher disease.

For further information, check out the report here

Read more insights at

Roots Analysis Leaders in Pharmaceutical & Biotechnology Market Research

You may also be interested in the following titles:

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If youd like help with your growing business needs, get in touch at [emailprotected]

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

[emailprotected]

Continue reading here:
Gene Therapy Pipeline Update: AVROBIO Receives Orphan-Drug Designation | Roots Analysis - The News Brok

The report covers the forecast and analysis of the Cell and Gene Therapy Consumables market on a global and regional level. The study provides historical data from 2015 to 2018 along with a forecast from 2019 to 2027 based on revenue (USD Million). The study includes drivers and restraints of the Cell and Gene Therapy Consumables market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the Cell and Gene Therapy Consumables market on a global level.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10172657

In order to give the users of this report a comprehensive view of the Cell and Gene Therapy Consumables market, we have included a competitive landscape and an analysis of Porters Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all the segments are bench marked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service & product launches, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the Cell and Gene Therapy Consumables market by segmenting the market based on product type, application/therapeutics, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2019 to 2027. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

A rise in the awareness about the gene & cell therapies will propel the market growth during the period from 2019 to 2027. Nevertheless, conducting randomized control tests will inhibit the expansion of the market during the forecast timeline. However, the growing trend for treating neurodegenerative ailments through the use of gene treatment will proliferate the market growth over the forecast period.

The expansion of the market during the forecast timespan is owing to the high frequency of chronic ailments including cancer and heart disorders. Apart from this, inflation in the occurrence of these disorders produces lucrative demand for enhanced therapies and this will culminate in the market demand over the forecast timespan.

Request For Full Report:https://www.kennethresearch.com/sample-request-10172657

Based on the product type, the market is sectored into Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media. Application/ Therapeutics- wise, the market for cell and gene therapy consumables are classified into Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology.

Some of the key players in the market include Amgen Inc., ATLANTA BIOLOGICALS, bluebird bio, Inc., Cook, Dendreon Pharmaceuticals, LLC, Fibrocell Science, Inc., General Electric, Kolon TissueGene, Inc., Orchard Therapeutics plc., Pfizer, Inc., PromoCell GmbH, RENOVA THERAPEUTICS, Sibiono GeneTech Co. Ltd., Spark Therapeutics, Inc., Vericel, Helixmith Co., Ltd., and Vitrolife.

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

Read more:
Cell and Gene Therapy Consumables Market 2020-2027/ Size, Segments and Supply Demand Forecast - StartupNG

The Global Gene Therapy Market report focuses on market size, status, and forecast 2020-2024, along with this, the report also focuses on market opportunities and threats, tactical decision-making, and evaluating the market. The Gene Therapy market report delivers data and information on changing investment structure, technological advancements, market tendencies and developments, capacities, and detailed information about the key players of the global market. In addition to this, the report also involves the development of the Gene Therapy market in the major regions across the world.

Cutting-edge released the research study on Global Gene Therapy Market, which deals a exhaustive overview of the factors influencing the global business scope. Gene Therapy Market research report shows the latest market insights, current situation analysis with upcoming trends, and breakdown of the products and services. The Gene Therapy Industry Report delivers key statistics on the market status, size, share growth factors of the Gene Therapy .

Get a PDF Sample Copy of this Gene Therapy Market Report:

https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#request_sample

Top Leading players of Gene Therapy Market Covered in the Report:

Bluebird BioSangamoSpark TherapeuticsDimension TherapeuticsAvalanche BioCelladonVical Inc.Advantagene

The report has enclosed key geographic regions such as Europe, Japan, United States, India, Southeast Asia and Europe. As far as the sub-regions, North America, Canada, Medico, Australia, Asia-Pacific, India, South Korea, China, Singapore, Indonesia, Japan, Rest of Asia-Pacific, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, Russia, Central & South America, Middle East & Africa are included.

Key Market Segmentation of Gene Therapy :

On the basis of types, the Gene Therapy Market from 2020 to 2024 is primarily split into:

Ex vivoIn Vivo

On the basis of applications, the Gene Therapy Market from 2020 to 2024 covers:

CancerMonogenicInfectious diseaseCardiovascular diseaseOther

Ask For Discount:

https://www.globalmarketers.biz/discount_inquiry/discount/130925

The Gene Therapy Market Research Report furthermore delivers a local examination of the market with a high focus on showcase development, development rate, and development potential. The research report calculates marketplace length estimate to analyze investment potentials and growth.

In this study, the years considered to estimation the market size of the Gene Therapy Industry Market: History Year: 2014-2018Base Year: 2018Estimated Year: 2019Forecast Year 2019 to 2024

The Gene Therapy market report provides answers to the following key questions:

Major Points Covered in Table of Contents:

For More Information and get a complete Table of content of Gene Therapy Market report:

https://www.globalmarketers.biz/report/automotive-and-transportation/global-automotive-gasoline-engine-turbocharger-market-2019-by-manufacturers,-regions,-type-and-application,-forecast-to-2024/130925#table_of_contents

Read more:
Global Gene Therapy Market 2020-2024 Expected To Witness The Highest Growth During Forecast period - Scientect

The global Gene Therapies for Cancer Treatment market study covers the projection size of the market both in terms of value (Mn/Bn US$) and volume (x units). The report estimates the lookup of different local distributors in the overall market and provides the market size of the Gene Therapies for Cancer Treatment market using both bottom-up and top-down approaches. To investigate the key players and their market contribution, primary and secondary research has been comprehensively performed. In addition, all the figures, subdivisions, and shares have been collected with the help of trustworthy sources.

In the Gene Therapies for Cancer Treatment market research study, 2018 is considered as the base year, and 2019-2029 is considered as the forecast period to predict the market size. The report identifies each Gene Therapies for Cancer Treatment market player on the basis of market share, production portfolio, and growth rate. In addition, the research study analyzes the strengths, weaknesses, opportunities and threats of the players.

Make An EnquiryAbout This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2692433&source=atm

Global Gene Therapies for Cancer Treatment market report on the basis of market players

The following players are covered in this report:Takara BioTocagenVBL TherapeuticsCold GenesysGenprexMomotaro-GeneMultiVirSynerGene TherapeuticsZiopharm OncologyAnchiano TherapeuticsCelgeneCelsionBluebird BioGene Therapies for Cancer Treatment Breakdown Data by TypeSomatic Cell Gene Therapy (SCGT)Germline Gene Therapy (GGT)Gene Therapies for Cancer Treatment Breakdown Data by ApplicationCancer Research CentersDiagnostic LaboratoriesCancer HospitalsOthers

The report provides market share, consumption pattern, and influencing factors of each region. Prominent countries driving the regional growth are also covered in the report.

Request Sample Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2692433&source=atm

Highlights of the report:

The Gene Therapies for Cancer Treatment market report answers the following questions:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2692433&licType=S&source=atm

See the original post here:
Gene Therapies for Cancer Treatment Market Projected to Witness Vigorous Expansion by 2019-2025 - Scientect

More and more robo-tech is evolving in an ironic turn that goes against many of the cold metal worlds in science fiction, where flesh has been taken over by machine. Maybe the most unexpected biomimetic literally mimicking biological creatures technology is a robot battery that stores energy like fat.

Sorry, Baymax, but robots will actually lose weight with a new "fat battery" (tech throughout history has often shed bulk with each upgrade).University of Michigan professor Nicholas Kotov a professor of chemical engineering, materials science and engineering, and macromolecular science and engineering has developed a zinc battery that could really level up the function of everything from nurse and server droids to delivery drones to micro- and nanobots. Smaller but much more energy-dense than the typical lithium ion battery, it can power a robot just as biological fat reserves can keep us going.

Such multifunctional batteries require mechanical strength, toughness, and stiffness.They should also be resilient against delamination, Kotov, who recently co-authored a study published in Science Robotics, told SYFY WIRE. Combining high-energy density with new mechanical properties was made possibleby designing new material for an ion-conducting membrane separating cathode and anode.This is how the batteries acquire these mechanical properties.The membrane between them was also designed with inspiration from biology; its nanofibrous structure is nearly identical to cartilage.

Kotov and his team demonstrated the power of these batteries (below) by creating a worm that resembles a robo-maggot and an epic scorpion that could possibly take down Scorponok in a Transformers death match.

Lithium ion batteries have nothing on these. Hydroxide ions passed on by a zinc electrode at the cathode (positive end) travel through that artificial cartilage to reach the anode (negative end) and transfer to the next battery. They are inflammable, unlike the electrolytes that can catch fire in lithium ion batteries. Aramid nanofibers in the cartilage are extraordinarily tough and can actually be upcycled from used body armor, while the gel component of it is water-based. Never mind that the battery itself is mostly nontoxic and costs much less to manufacture than that lithium ion one in your smartphone.

Kotov heads a lab with a focus on developing biomimetic nanostructures, and his research team wanted to figure out a more efficient way of storing energy in robots. Bots can be held back by the weight, cost, and overall restrictiveness of the usual batteries. Living organisms store energy very differently from batteries. Humans and other creatures have fat cells distributed all over the body, holding on to reserves of lipids that are burned when there is not enough energy intake to sustain them. There is no fat storage sac, which is basically what a battery is to a robot. The biomorphic batteries developed in Kotovs lab translate biology into technology.

Fat gets too much of a negative rap. Besides being an instant energy reserve, it protects internal organs, influences hormone and stem cell production, and functions as built-in thermal insulation.

These biological concepts can be put in the foundation of the batteries for robots, said Kotov. This is exactly what we have done in this project.We distributed the batteries over the entire body of the robot and made them multifunctional.Besides storing energy, our batteries also protect robot organs.

The only downside of the battery is that it can only keep up high capacity for about 100 cycles, compared to a lithium ion batterys average of 500. Zinc is the culprit because it ends up forming spikes that mean doom for the artificial cartilage membrane and the life of the battery. At least there should be no problem recycling and replacing the materials. Eventually, fat batteries could replace the entire exterior of a robot for an unreal 72 times more power capacity than one lithium ion battery. But would that impact the size of a robot? And with that, where it would be able to go and what tasks it would be capable of? Not according to Kotov.

Robots with biomorphic fat-like batteries do not need to be enormous, he said. In fact they are slimmer, lighter, and more agile than the original ones because we removed the bulky cumbersome part.The potential drawback is that this energy storage becomes more complex, but is the tradeoff for greater efficiency and range.

So these robots are more likely to deliver your pizza than eat it, and they wont even let it get cold.

See the original post here:
Robots can now store energy like we store fat, and they dont even need to eat pizza - SYFY WIRE

NIH grant funds an interdisciplinary effort among researchers from University of Southern California; University of Washington and Fred Hutchinson Cancer Research Center; Harvard University and Massachusetts General Hospital; the Ragon Institute; and Magenta Therapeutics

Magenta will utilize its tool CD45 and CD117 antibody-drug conjugate (ADC) conditioning agents, as well as its stem cell biology platform to identify the optimal strategy for curative immune system transplant in patients with HIV

Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced it is part of a multi-project, broad-based research effort awarded a five-year, $14.6 million U19 grant from the National Institutes of Health (NIH) to explore gene- and cell-based approaches to advance research into curing HIV.

This cross-institutional research program brings together leaders in the fields of gene editing, HIV and stem cell transplant. The team, which includes researchers from the University of Southern California, the University of Washington, the Fred Hutchinson Cancer Research Center, Harvard University, Massachusetts General Hospital; the Ragon Institute and Magenta Therapeutics, will explore novel hematopoietic stem and progenitor cell (HSPC) engineering and transplantation approaches aimed at achieving complete remission of HIV-1 infection.

"We are excited to collaborate with our colleagues in this important multi-institution research team to help advance gene editing approaches with our novel targeted antibody drug conjugate (ADC) conditioning platform to one day be able to cure patients living with HIV," said John Davis Jr., M.D., M.P.H., M.S., Head of Research & Development and Chief Medical Officer, Magenta. "These studies leverage our proprietary stem cell biology pipeline and ADC platform to provide important insights into which conditioning strategy is best suited to aim for HIV."

Story continues

Magenta will utilize its conditioning technology to optimize cell dose in animal models and determine whether targeted conditioning and gene-modified HSPC transplant enables disease control.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption "Risk Factors" in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005248/en/

Contacts

Magenta Therapeutics: Lyndsey Scull, Director, Corporate Communications202-213-7086lscull@magentatx.com

Dan Budwick1ABdan@1abmedia.com

Go here to see the original:
Magenta Therapeutics Named Co-Recipient of Grant from the National Institutes of Health to Explore Use of Novel Targeted Conditioning Agents with Gene...

In a society focused on visual communication, being blind can have severe disadvantages. In fact, research shows blind people are at higher risk of unemployment, social isolation, and lower quality of life than sighted people. Given the huge impact blindness has on society and those without vision, the drive to find a cure for blindness has become a profitable market.

Many new, cutting-edge developments that cure blindness build on promises they often cannot keep, leaving many blind people and their families feeling disappointed and disillusioned. But what does curing blindness actually mean and how can it be achieved in a way that it most benefits the blind person?

When we think of curing blindness, we often think about restoring the lost sense for example, through vision-enhancing technology, bionic eyes, or gene therapy. This is because we typically treat an impaired sense by focusing on the damaged sensory organ. But while our eyes deliver the sensory input, by transforming light into electrical impulses that our brains can use, most visual perception happens in the brain.

The perception of a visual object, a coffee cup, say, is created across different hierarchical levels in the visual cortex of our brain. Simple two-dimensional features, such as edges and colours, are combined into more complex shapes, which are in turn combined into the perception of whole objects, like our coffee cup. Across these different levels, our previous visual and non-visual experiences strongly influence how we perceive the final object.

Because of the complex nature of visual perception, sight is incredibly difficult to restore, and achieving a satisfactory level of visual function is not easy. Despite significant advances in visual restoration technology, even the best visual implants typically only allow visual acuity of 1/60, which is technically still classed as blindness by the World Health Organization. While this minimal form of light perception is already great progress, its not enough to allow a person to live independently.

While every blind person has their own ideas of what sight rehabilitation should do for them, what resonates with most is the aim to increase independence by allowing blind people to gain more access to visual information.

But does the brain need vision for that? Not necessarily. This is why we need to adopt a different perspective on sensory rehabilitation one that views vision as part of a greater multisensory experience. After all, perception is rarely based on one sense alone but on a combination of multisensory experiences in which our senses influence each other.

The brain has the remarkable ability to compensate for sensory loss by reorganizing how it processes information. In fact, the brain learns to perceive through the sensory experiences it makes during childhood. If all sensory experience is non-visual, perception will develop around these experiences. So if a person was born without sight, or lost their sight early on in childhood, their perception will develop around the non-visual senses.

This is why, on some tasks, blind people perform better than sighted people, while, on other tasks, they may perform worse. This dichotomy seems to underlie a simple principle: is the sense that is typically used for this task the best suited for accessing this information? For example, we are well able to locate a buzzing phone using either our vision or hearing. In this case, more experience finding objects through sound will lead to superior performance in blind people when only hearing is used. However, given that our vision is much better suited to perceiving peoples faces, blind people usually perform worse than sighted people when recognising others faces through touch.

We know that the brain learns best about the environment when it can access the same information through multiple senses. This benefits our perception by enhancing accuracy and precision. But if we want to make use of this perceptual benefit in vision rehabilitation, we need to know whether the blind brain actually learned to generate it.

It turns out that this depends on the age a person goes blind. Blindness before the age of eight or nine years influences how touch and hearing are used together to estimate object size. But blindness after this age impairs the ability to enhance perception through multisensory combination.

So what does that mean for sensory rehabilitation? We know that theres not one best solution for all, but we also know that the age of blindness-onset can provide important clues. If a person has been blind since birth or early childhood, the brain does not know how to process visual information, so vision restoration may not bring much benefit. If, however, sight was lost later in life, the brain is best wired to perceive its surroundings through vision.

But theres still good news for the congenitally and early blind: the enhanced perceptual abilities in the remaining senses can be used to substitute vision. In fact, visual information does not have to be taken up through the eyes it can also reach the brain through our other senses. In order for that to happen, it first needs to be translated into a different sensory language. For example, visual information can be directly translated into sound. Through training, the brain then learns to use this new sensory language, opening up the visual world through the use of another sense.

While sensory restoration advancements have come a long way, we are still far from an optimal solution that allows blind people to access visual information and equally partake in society. By realising that perception depends on individual experiences, we can better develop solutions that will most benefit each person whether that aims to restore their sight, or seeks to use their other senses instead.

Read the original here:
'Curing blindness': why we need a new perspective on sight rehabilitation - The Conversation UK

A Hungarian researcher has won theKrber Prize for European Science 2020 in Hamburg, Germany, earning him a1 million($1.18 million) check in the process.

Botond Roska, who works in the Swiss city of Basel, has uncovereda gene-based therapy that reprograms cells in the human eye so that they can perform the work of the light-sensitive receptors needed for human vision, according to the Krber Foundation that hands out the annual prize. It is hoped the procedure willreactivate the retinas of the blind.

Read more:India: Being blind during the coronavirus pandemic

The medical scientist said that, for the time being,the processcreates a level of vision similarto watching television in black and white. Clinical testson blind volunteers are already underway as a result of the Budapest-born researcher's groundbreaking work.

"Roska's research has woken up hope that new treatment methods might restore the ability to see in the blind,"said Hamburg Mayor Peter Tschentscher at theceremony on Monday.

The Krber Foundation's prize was first awarded in 1985, and it recognizesscientists whose work has applied futuristic techniques to physical sciences.

The son of a computer scientist and a pianist, Roska began his career in medicine "after a detour," said Tschentscher. The scientist first studied the cello at the Liszt Ferenc Academy of Music in Budapest, but had to give up the instrument following an injury. He thenbegan to pursue medicine and mathematics.

Last year's winner of the prestigious prize was German artificial intelligence scientistBernhard Schlkopf of the Max Planck Society.

jsi/dj (dpa, EPD)

Originally posted here:
Hungarian researcher wins award for procedure that could cure blindness - DW (English)

Managing a broiler flock for top performance takes attention to detail. However, with many years of experience under the belt and knowledge of the inner workings of your farm, farm blindness is a point to consider.

You can only recognise an irregularity if you know what is normal. You will learn what is normal by observing as often and as objectively as possible. Always be aware of the dangers of farm blindness.

By definition farm blindness is when you see the situation on your own farm as the norm. Limit farm blindness by talking to colleagues and advisors on a regular basis and really share all critical and even sensitive data. Act on critical comments. Also go and look at other poultry keepers operations.

Join a study group to share opinions and ideas on a regular basis and improve together.

Find out more about African Swine Fever at our ASF section page

Continued here:
PoultryWorld - How to prevent farm blindness? - Poultry World

Corneal blindness is the 4th most common type of blindness that affects the global population. However, it is also much easier to cure than many people might realise. In fact, with continued effort and research, this affliction might even be completely curable by 2035. Lets take a look at how this could come to pass.

Corneal blindness is described as a decrease in vision or even a complete loss of vision due to a disease of the cornea. There are several causes of this, including a vitamin A deficiency, eye trauma, or an infection of some sort.

Though it only affects 5% of the worlds blind population, it is still understandably devastating for those who have to live with this condition. It is also frequently found amongst populations that do not have the highest standard of living. If the main breadwinner of a family unit develops corneal blindness, it can have a massive knock-on effect for the rest of the family.

How Do We Treat Corneal Blindness?

Luckily, corneal blindness can be easier to treat than other types, and it can even fully restore someones sight to them. This is usually done with a corneal transplant. The cornea is the clear outer layer of your eye and it is an option for those who are filling out organ donor lists. Corneal transplants are one of the most common types of transplants that happen around the world.

Obviously, no transplant surgery can be described as cheap, and the people who need it the most often come from very poor areas or backgrounds. That is why the work of people like Tej Kohli and the Save Sight Registries are so important. They are helping those who need the treatment the most to get the help they need at no cost to them. It is a selfless pursuit, that could impact millions of lives.

How Do We Eradicate Corneal Blindness?

Treating corneal blindness is only the first step we need to take. It is also incredibly important that we put in plenty of steps to prevent further cases developing. Since corneal blindness is often caused by environmental factors, this can make it easier to do than something that could be primarily hereditary.

By making sure that people have a good standard of living at home and supplying PPE to dangerous worksites where the eye could be harmed, we will be able to prevent many cases of corneal blindness before they take root. This is incredibly important and could help to make numbers drop rapidly.

With this two-pronged attack between treatment and cause, we should see a decrease in the number of cases. This will soon put us well on the track to eradicating corneal blindness by 2035. Doing so will be a massive step forward in not just our lives but in medical science too. Who knows what we could learn as we fight to eradicate this illness throughout the world?

To find our more about theThe Tej Kohli Foundation visit their website http://www.tejkohlifoundation.com

See the original post:
Can corneal blindness be eradicated by 2035? | HeraldScotland - HeraldScotland

Imagine trying to pass to a team-mate or avoid an opponent, but you can't because this is what you see...

From the grassroots to the highest professional level, colour blindness can impact the performance of players and coaches, spoil the enjoyment of watching sport (live or on TV), and affect commercial deals.

Kit clashes, coloured footballs under floodlights, signage and multi-coloured digital content can be problematic for people affected. A staggering one in 12 men suffer from colour blindness, and one in 200 women, amounting to a worldwide community of over 300 million people.

Despite this statistic, all too often colour blind fans find themselves unable to tell the teams apart, buy tickets independently or even see the ball.

Throughout the season, colour blind fans take to social media to vent their frustration and make the leagues and broadcasters aware of their ongoing oversight. In the Premier League during the last campaign, there were constant kit clashes being flagged up by viewers.

This is common across leagues around the world, and also in the international game. The same questions are asked of Fifa and Uefa during major tournaments, with many high-profile matches causing difficulty.

This is not just a problem for viewers, but players too.

Very few players are publicly colour blind, some due to lack of awareness, and others to avoid the risk of it damaging their chances of getting selected.

Coaches face similar issues, with equipment and training wear often invisible or difficult to distinguish between.

There is growing pressure on the key stakeholders, and some steps are beginning to be made to help raise awareness and consider colour blind people in all aspects of the game.

As far back as 2014, the FA Cup swapped its traditional white for a new pink Nike football, designed to be highly visible. However, it was clearly anything but, with colour blind people unable to distinguish the ball from the pitch.

After attracting fierce criticism from fans and commentators alike, the FA swapped back to a mainly white ball just a few months after release.

The FA has been active in campaigning and educating people ever since, releasing this animationexternal-link last year to give people an appreciation of the challenges faced by players and fans. In partnership with Uefa, it co-authored colour blindness guidelines that are now being adopted by more clubs and national associations.

Last season in the Premier League, Burnley were instructed by the Premier League not to wear their alternative green strip in their match against West Ham, prompting the release of a speedily designed, special edition white kit to avoid any clashes.

This weekend, Nations League matches will be the focal point for this year's Colour Blind Awareness Day (6 September), with many leading national associations and players participating in a campaign. Through a European Union-funded scheme run by Tackling Colour Blindness In Sport, the likes of Portugal and Manchester United's Bruno Fernandes and Iceland and Everton's Gylfi Sigurdsson have pledged their support.

"Not being able to watch a match on TV in full colour, to help easily distinguish between teams, referee cards and coloured objects in the stands seems almost unimaginable to me," said Fernandes.

"None of my team-mates has identified as colour blind but for sure there are many in football who may face a range of difficulties when playing or watching the game.

"That's why it's so important to raise awareness, provide greater information and make changes so that those who live with colour blindness don't feel left out and experience the game to the fullest."

Sigurdsson has experienced the issues first hand.

"I was at Reading's academy for many years with a colour blind player, Nicholas Bignall, who went on to play at a Premier League club. At the time I didn't realise he was colour blind and didn't appreciate until now how much more challenging training was for him if we used equipment he couldn't tell apart. This must have made it much more difficult to earn a place in the squad at times."

Matt Holland, best known for his time with Ipswich, Charlton and the Republic of Ireland, is an example of a player who had to deal with colour blindness while competing at the top level.

"Generally I was OK in games but occasionally struggled when the kits were quite close colour wise. The biggest challenge was having to take a split second longer to make a decision on where I was going to pass the ball to make certain I was passing to a team-mate."

"As a commentator now, I think it is imperative that colours of opposition sides are vastly different, and it would be helpful if the numbers on the back of shirts were more visible."

Despite ongoing kit clashes and social media frustrations, slow progress is clearly being made by the decision makers of football.

"The good news is that implementing procedures to assist and protect those with colour blindness in sport is relatively simple," said Kathryn Albany-Ward, founded of Colour Blind Awareness.

"Much of the time, all that's needed is a little goodwill and forward planning, and solutions can have positive benefits for teams, fans, sponsors and broadcasters."

Read this article:
Colour blindness in football: Kit clashes and fan struggles - what is being done? - BBC Sport

While you might be inclined to think that any hand sanitizer you pick up off a store shelf is safe to use, the sad reality is that some hand sanitizers have proven to be toxic, and in some instances, deadly. As weve highlighted previously, the FDA over the past few months has banned approximately 170 hand sanitizer brands due to the presence of methanol, a toxic substance that can cause a myriad of serious health complications.

Also known as wood alcohol, methanol has been found to cause seizures, permanent blindness, vomiting, and a range of other symptoms in users. In some tragic cases, it has even resulted in death when ingested by children.

Consumers who have been exposed to hand sanitizer containing methanol should seek immediate treatment which is critical for potential reversal of toxic effects of methanol poisoning, the FDA said in a letter a few months back.

Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system or death, the statement adds.

Up until now, identifying potentially dangerous hand sanitizer brands has been somewhat easy given that nearly every offending brand was manufactured in Mexico. Recently, though, the FDA identified a dangerous hand sanitizer brand that was traced back to Florida.

As reported by the Miami Herald, a hand sanitizer brand manufactured by a Coral Gables company and distributed in Miami was found to contain methanol. The brand was quickly added to the FDAs banned list, a move which was accompanied by a recall.

AJR Trading recalled lot No. 20DF8307 of bio aaa Advance Hand Sanitizer in 480 ml bottles, expiration date April, 2022, after the FDA said its testing found methanol. Methanol, also known as wood alcohol, can be toxic if rubbed into the skin, according to the FDA.

The FDA adds that the company voluntarily recalled 2,004 units of the product due to the possible presence of methanol. Its worth noting that the company, to date, hasnt received any reports of users experiencing any adverse reactions to the product.

The FDA adds:

Consumers with questions regarding this recall can contact AJR Trading by phone insert 305-302-8416 or e-mail to ajrtrading15@gmaill.com Monday to Friday from 10:00 am to 5:00 pm Central Time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

A partial list of other banned hand sanitizer brands identified by the FDA can be seen below:

The full list of banned hand sanitizer brands can be viewed over here.

A life long Mac user and Apple enthusiast, Yoni Heisler has been writing about Apple and the tech industry at large for over 6 years. His writing has appeared in Edible Apple, Network World, MacLife, Macworld UK, and most recently, TUAW. When not writing about and analyzing the latest happenings with Apple, Yoni enjoys catching Improv shows in Chicago, playing soccer, and cultivating new TV show addictions, the most recent examples being The Walking Dead and Broad City.

Excerpt from:
The FDA just banned a toxic hand sanitizer made and distributed in the USA - BGR

From serving as a spokesperson for Foundation Fighting Blindness Canada, to becoming a motivational speaker, and then working full-time as an influencer with more than 2 million YouTube subscribers, Molly Burke is a force to be reckoned with. The 26-year-old also happens to be blind something she strives to educate the masses about in order to smash stereotypes and highlight societal barriers faced by the blind community.

But is Molly Burke fully blind? Keep reading to learn more.

Molly often gets bullied online because random strangers don't believe she's actually blind and the relentless misconceptions about people who are blind are often to blame.

In 2016, she published a YouTube video titled "Top 5 Reasons Why People on YouTube Think I'm Not Blind," during which Molly shared some people believe she's not fully blind because she can type. Except, as she pointed out in the video, there is an abundance of technology available to assist people with vision impairment / blindness to communicate (like talk-to-text, for example).

Another reason some are skeptical about Molly's blindness is because of the language she uses.

"For me, when I used the word 'watching,' obviously I don't mean physically watching with my eyes the way a sighted person would watch," she explained. "But for me, the word 'watching' means 'listening' it's interchangeable for me ... and yes, I'm still going to use the word 'watch,' and 'look,' and 'saw,' and 'see.' And that doesn't mean I'm faking my blindness."

Others mistakenly assume Molly must be able to see because her eyes don't appear to have anything physically "wrong" with them. "'You can't be blind, your eyes are blue,' or, 'You can't be blind, your eyes look normal,' or 'Your eyes are too pretty for you to be blind,'" are all comments she said she's fielded.

(For the record, Molly does have nystagmus, which causes her eyes to shake although it's not super noticeable.)

Here's another reason some people think Molly isn't actually blind: She's able to look directly at the camera.

"As a blind person, I'm still able to easily look at a camera because number one, it's not that hard to look straight forward, where the camera is straight ahead of you," she explained. "And number two, I use a ring light, which is a light that sits right on top of my camera and I have light perception, so I just look and see where the light is and then look directly below and know that is where my lens is. So that's where I have to look."

Still others wonder why Molly doesn't wear dark sunglasses if she's fully blind.

"This is a huge stereotype about the blind community that's not true," she said. "Yes, some blind people wear dark sunglasses when they're inside and outside. Yes, some blind people, including often myself, wear dark sunglasses when we're outside. And some blind people don't wear sunglasses ever, at all."

So yes, Molly Burke is truly, fully blind despite the fact that she doesn't wear sunglasses, doesn't have anything "wrong" with how her eyes physically appear, can type, can look into her camera lens, and uses phrases like "watching TV." And with the help of social media, she's working to continue smashing these stereotypes and more every day.

Original post:
Is Molly Burke Fully Blind? The Influencer Faces Regular Bullying - Distractify

In a letter dated August 13, 2020, Senators Ron Wyden and Jeff Merkley and Representatives Earl Blumenauer and Suzanne Bonamici, all of Oregon, requested that the EPA investigate the impact of tear gas use on people, air, land, and bodies of water.

LuizSouza / Shutterstock.com

The letter pointed out possible side effects the use of the chemicals might have, as well as potential long-term impacts.

In addition to the direct health impacts on our constituents, we are also deeply concerned about the impact tear gas has had on Oregons environment, the letter says. State and local environmental and health agencies are investigating its impacts, and it is also the duty of the Federal Government to provide information that will help further these studies and make information about the environmental impacts of tear gas usage readily available to the American public.

According to the Centers for Disease Control and Prevention, long-term exposure can cause blindness, glaucoma, immediate death from chemical burns and respiratory failure.

Tear gas is the generic term for a class of compounds that cause a burning sensation, according to a report by ProPublica. Most law enforcement agencies in the U.S., including the Philadelphia Police Department this week, use a chemical called CS, short for 2-chlorobenzalmalononitrile. CS activates a specific pain receptor, one thats also triggered by eating wasabi, said Sven-Eric Jordt, a professor of anesthesiology at Duke University. But CS is much more powerful, up to 100,000 times stronger than the sting from wasabi, he added.

They are really pain nerve gases, Jordt said. They are designed to induce pain.

Numerous medical and public health professionals have also noted that respiratory irritation from exposure to CS gas has the potential to increase the risk for COVID-19.

The Oregon state leaders sent the letter because Portland courthouse personnel were seen hosing tear gas off the sidewalks and streets around the courthouse after it was utilized as a riot control method. These chemicals were washed into storm drains and other groundwater sources.

The letter asks for the following specific information:

Because tear gas is often deployed as a method of riot control in all states and use of the gas has been widespread in many states in recent months, discovering the potential long-term impacts of the use of these chemicals is important.

Go here to read the rest:
Senators and Representatives Ask EPA to Study Impact of Tear Gas on Environment - EHS Daily Advisor

Photo: Alexi Rosenfeld/Getty Images

That wearing a mask is an effective way of reducing the spread of COVID-19 is well-established at this point. Both the Centers for Disease Control and Prevention and the World Health Organization recommend that people wear masks in public spaces where social distancing is not possible. That alone should be reason enough for you to mask up before walking out the door, but there is another possible benefit to wearing a face covering in public: not getting recognized by acquaintances on the street.

According to a new report from the New York Times, the widespread use of masks in the United States has made facial recognition increasingly difficult for many people in some cases, to an extent thats equivalent to having face blindness. In a recently published study, Dr. Erez Freud, a psychologist with the Centre for Vision Research at York University in Toronto, and his co-authors found that participants struggled to recognize faces that had surgical-style masks covering their noses and mouths. Of the nearly 500 adults who completed a facial-memory exercise online, 13 percent had so much trouble identifying masked faces that, per the Times, they may as well have suffered from prosopagnosia, or face blindness. Comparatively, only 3.5 percent scored that low in identifying people without masks.

A mask doesnt grant total anonymity, of course. Research has found that people rely most heavily on the eyes when identifying someone (I can personally confirm this: Once, I was pretty sure I saw Jake Gyllenhaal walking by my old office in Tribeca, but he was wearing sunglasses so I couldnt be 100 percent certain).

The report also found that the observers culture influenced their ability to perceive people wearing masks. Studies from 2009 and 2015 found that participants from Egypt and the United Arab Emirates countries where headscarves are more common were better than American or British participants at identifying faces where only the eyes, nose, and mouth were showing.

Struggling to identify faces can present real challenges in identifying and communicating with people (it can be more difficult to read peoples emotions, for example). Given that were all in the same boat right now, though, consider the possible upsides. Imagine, for instance, walking down the street by your apartment and constantly crossing paths with the guy you briefly dated who really tried to get you into the Joe Rogan Experience. Previously, youd both pretend to suddenly be consumed with something on your phones, and hurry past each other with heads bent. Now, you can both walk freely, spines straight, faces masked, blissfully unaware of each others presence, burdened only by absolutely every other terrible thing that is going on in the world. A dream!

Get the Cut newsletter delivered daily

Read more:
Its a Golden Age for Pretending Not to Notice Acquaintances on the Street - The Cut

Published 7:58pm EDT, Friday, September 4, 2020

Mr. Miles is an eight-year-old orange and white shorthair who is blind but he lives a pretty normal cat life. Mr. Miles also enjoys the company of others around him and he would do well living with other cats and dogs. Although he has not had much experience with children, he is a good cat and is willing to consider sharing his home with kids who can be gentle and respectful of pets. Mr. Miles definitely has lots of life to live and love to give. Please ask the adoption counselor to explain his blindness when you apply for a visit with Mr. Miles in Newington. Applications for adoption can be obtained at https://cthumane.org/adopt/all-adoptable-pets/. To learn more about operations during COVID-19, go to https://cthumane.org/adopt/adoption-process/.

Mr. Miles is an eight-year-old orange and white shorthair who is blind but he lives a pretty normal cat life. Mr. Miles also enjoys the company of others around him and he would do well living with other cats

Mr. Miles is an eight-year-old orange and white shorthair who is blind but he lives a pretty normal cat life. Mr. Miles also enjoys the company of others around him and he would do well living with other cats and dogs. Although he has not had much experience with children, he is a good cat and is willing to consider sharing his home with kids who can be gentle and respectful of pets. Mr. Miles definitely has lots of life to live and love to give. Please ask the adoption counselor to explain his blindness when you apply for a visit with Mr. Miles in Newington. Applications for adoption can be obtained at https://cthumane.org/adopt/all-adoptable-pets/. To learn more about operations during COVID-19, go to https://cthumane.org/adopt/adoption-process/.

Mr. Miles is an eight-year-old orange and white shorthair who is blind but he lives a pretty normal cat life. Mr. Miles also enjoys the company of others around him and he would do well living with other cats

Pet of the week: Mr. Miles

Mr. Miles is an eight-year-old orange and white shorthair who is blind but he lives a pretty normal cat life. Mr. Miles also enjoys the company of others around him and he would do well living with other cats and dogs. Although he has not had much experience with children, he is a good cat and is willing to consider sharing his home with kids who can be gentle and respectful of pets. Mr. Miles definitely has lots of life to live and love to give. Please ask the adoption counselor to explain his blindness when you apply for a visit with Mr. Miles in Newington. Applications for adoption can be obtained at https://cthumane.org/adopt/all-adoptable-pets/. To learn more about operations during COVID-19, go to https://cthumane.org/adopt/adoption-process/.

{{captions}} {{credits}} {{resaleLink}}

Visit link:
Pet of the week: Mr. Miles - Torrington Register Citizen